State Street SPDR S&P Biotech ETF (XBI) Stock Price & Analysis
State Street SPDR S&P Biotech ETF (XBI) is trading at USD 153.69, up 0.29% today, as of October 21, 2026 at 17:51 UTC (US market open; quotes may be delayed), according to Nexqual market data.
XBI last closed at USD 153.24; today's session has ranged USD 153–155.78 on volume of 5,602,951 shares. Market capitalization is —, with a 52-week range of USD 106.3–169.89 (PCX). Source: Nexqual, retrieved October 21, 2026 at 17:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/XBI.md
Key facts (XBI)
- Total return with dividends: 1Y +40.9% vs S&P 500 +16.5%; 5Y +24.6% vs S&P 500 +82.6%.
Total return (dividends reinvested) (XBI)
| 1Y (from 2025-10-21) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +40.9% | +24.6% |
| S&P 500 (SPY) | +16.5% | +82.6% |
| Per year | +40.9% | +4.5% |
| Volatility (annualized) | 29.0% | 29.8% |
| Max drawdown | -14.9% (Aug 2026→Oct 2026) | -51.2% (Nov 2021→Oct 2023) |
XBI options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 23, 2026 | 2 | 35.4% | ±2.2% |
| Oct 30, 2026 | 9 | 34.4% | ±4.4% |
| Nov 6, 2026 | 16 | 34.1% | ±5.7% |
| Nov 13, 2026 | 23 | 34.8% | ±7.0% |
| Nov 20, 2026 | 30 | 33.8% | ±7.8% |
| Nov 27, 2026 | 37 | 33.8% | ±8.6% |
| Dec 18, 2026 | 58 | 32.0% | ±10.2% |
| Jan 15, 2027 | 86 | 31.8% | ±12.4% |
30-day implied volatility 32.5% vs 31.9% realized over the last 30 trading days. Put/call ratio (volume) 0.4. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 21, 2026 at 17:51 UTC)
| Price | USD 153.69 |
|---|---|
| Change | ▲ 0.29% (up) |
| Previous Close | USD 153.24 |
| Open | USD 153.37 |
| Day Range | USD 153 – 155.78 |
| 52-Week Range | USD 106.3 – 169.89 |
| Volume | 5,602,951 shares |
| Market Cap | — |
| Exchange | PCX |
Technical Analysis (XBI)
Nexqual's technical model rates XBI "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of October 21, 2026 at 17:51 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.13 (neutral) |
| vs SMA50 | Below (USD 157.59) |
| MACD | -2.01 (negative) |
Financial Health Score (XBI)
Nexqual rates State Street SPDR S&P Biotech ETF's overall financial health "Mixed" across five dimensions, as of October 21, 2026 at 17:51 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Mixed — No data |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IBB | iShares Biotechnology ETF | USD 212.18 | ▲ 0.8% |
| XLV | State Street Health Care Select | USD 178.43 | ▼ 0.77% |
| XLI | State Street Industrial Select | USD 168.68 | ▲ 1.13% |
| XLK | State Street Technology Select | USD 188.72 | ▲ 1.77% |
| XLF | State Street Financial Select S | USD 56.07 | ▲ 0.63% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 21, 2026 at 17:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt